INTS.US Intensity Therapeutics, Inc. Common stock

Healthcare Biotechnology USA Stocks
3.08 USD
Close of Nov 15, 2026
2.80 15.00
Market cap
USD 10.2M
P/E
-
P/B
1.33x
ROE
-156.6%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is INTS.US undervalued?

Graham number

The Graham number of Intensity Therapeutics, Inc. Common stock cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Intensity Therapeutics, Inc. Common stock fundamental analysis

No fundamental analysis for Intensity Therapeutics, Inc. Common stock yet.

Intensity Therapeutics, Inc. Common stock stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Intensity Therapeutics, Inc. Common stock

Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer relapse and metastasis in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headqua…

Full company profile